12
Participants
Start Date
May 31, 2016
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
AB-SA01 (10^8 PFU per phage)
Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
AB-SA01 (10^9 PFU per phage)
Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Placebo (for Cohort 10^8)
Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Placebo (for Cohort 10^9)
Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Clinical Trials Center, WRAIR, Silver Spring
Lead Sponsor
Walter Reed Army Institute of Research (WRAIR)
FED
Armata Pharmaceuticals, Inc.
INDUSTRY